See more : 360 One Wam Limited (360ONE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Cingulate Inc. (CINGW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cingulate Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- United Parks & Resorts Inc. (PRKS) Income Statement Analysis – Financial Results
- Dynex Capital, Inc. (DX-PC) Income Statement Analysis – Financial Results
- Seiko Epson Corporation (SEKEF) Income Statement Analysis – Financial Results
- Grupo Financiero Inbursa, S.A.B. de C.V. (GFINBURO.MX) Income Statement Analysis – Financial Results
- Teijin Limited (3401.T) Income Statement Analysis – Financial Results
Cingulate Inc. (CINGW)
About Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 582.92K | 621.99K | 808.44K | 842.35K | 178.91K |
| Gross Profit | -582.92K | -621.99K | -808.44K | -842.35K | -178.91K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 15.49M | 9.00M | 8.41M | 5.09M | 9.09M |
| General & Administrative | 7.27M | 8.51M | 12.27M | 1.99M | 2.30M |
| Selling & Marketing | -583.03K | 0.00 | 0.00 | 0.00 | 250.00K |
| SG&A | 7.27M | 8.51M | 12.27M | 1.99M | 2.55M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.76M | 17.50M | 20.68M | 7.08M | 11.65M |
| Cost & Expenses | 22.76M | 17.50M | 20.68M | 7.08M | 11.65M |
| Interest Income | 775.76K | 174.51 | 0.00 | 100.25 | 100.96 |
| Interest Expense | 0.00 | 174.00K | 0.00 | 54.61K | 0.00 |
| Depreciation & Amortization | 582.92K | 621.99K | 808.44K | 842.35K | 178.91K |
| EBITDA | -22.95M | -17.05M | -19.87M | -6.29M | -11.37M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.76M | -17.50M | -20.68M | -7.08M | -11.65M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -775.76K | -174.51K | -30.59K | -100.25K | 101.40K |
| Income Before Tax | -23.53M | -17.68M | -20.71M | -7.18M | -11.55M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 174.00K | 30.50K | 99.34K | -100.53K |
| Net Income | -23.53M | -17.85M | -20.74M | -7.28M | -11.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -311.99 | -378.81 | -440.14 | -154.57 | -242.89 |
| EPS Diluted | -311.99 | -378.81 | -440.14 | -154.57 | -242.89 |
| Weighted Avg Shares Out | 75.44K | 47.12K | 47.12K | 47.12K | 47.12K |
| Weighted Avg Shares Out (Dil) | 75.44K | 47.12K | 47.12K | 47.12K | 47.12K |
Source: https://incomestatements.info
Category: Stock Reports